Literature DB >> 6423731

A solid-phase enzyme immunoassay for C-reactive protein: clinical value and the effect of rheumatoid factor.

J Highton, P Hessian.   

Abstract

Measurement of serum C-reactive protein (CRP) concentration is useful in monitoring the progress of chronic inflammatory diseases. Rheumatoid factor, by its interaction with the Fc portion of IgG, has the potential to interfere with solid-phase immunoassays for CRP and other serum proteins. To determine the effect of RF on a solid-phase enzyme immunoassay for CRP we compared assays employing whole antisera or F(ab')2 fragments. In 92 sera with RF latex titres ranging from 1/80 to 1/81,920, no correlation was found between RF concentrations and CRP measurements. CRP concentrations measured by use of whole antisera (mean +/- standard error of the mean, 59.7 +/- 5.7 mg/l, n = 92) were lower than those measured with F(ab')2 fragments (62.5 +/- 5 mg/l), indicating that exaggeration of CRP measurements did not occur in RF containing sera under the conditions of the assay. Our results show that in the CRP-ELISA, interference from RF was precluded by the high serum dilutions employed. At lower serum dilutions RF binding was detected. Consequently, in solid-phase enzyme immunoassays at lower serum dilutions the presence of RF may lead to false positive results and exaggerated measurements.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423731     DOI: 10.1016/0022-1759(84)90149-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.

Authors:  Xiangdan Wang; Valerie Quarmby; Carl Ng; Anan Chuntharapai; Theresa Shek; Charles Eigenbrot; Robert F Kelley; Steven Shia; Krista McCutcheon; John Lowe; Cecilia Leddy; Kyle Coachman; Gary Cain; Felix Chu; Isidro Hotzel; Mauricio Maia; Eric Wakshull; Jihong Yang
Journal:  MAbs       Date:  2013-04-29       Impact factor: 5.857

2.  Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure.

Authors:  S J Wigmore; T S Walsh; A Lee; J A Ross
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

3.  Measurement of plasma concentrations of polymorphonuclear elastase-alpha 1 proteinase inhibitor (elastase-alpha 1 antitrypsin) in patients with rheumatoid arthritis: interference by rheumatoid factor.

Authors:  R E Banks; S W Evans; K F Taylor; H A Bird; J T Whicher
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

4.  Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Authors:  A Familian; A E Voskuyl; G J van Mierlo; H A Heijst; J W R Twisk; B A C Dijkmans; C E Hack
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

5.  Occurrence of C-reactive protein in cryoglobulins.

Authors:  S M Weiner; V Prasauskas; D Lebrecht; S Weber; H H Peter; P Vaith
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

6.  Low grade inflammation, as evidenced by basal high sensitivity CRP, is not correlated to outcome measures in IVF.

Authors:  Sarah Robinson; Phil Pemberton; Ian Laing; Luciano G Nardo
Journal:  J Assist Reprod Genet       Date:  2008-09-23       Impact factor: 3.412

7.  IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells.

Authors:  C Gabay; B Genin; G Mentha; P B Iynedjian; P Roux-Lombard; P A Guerne
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

8.  In women with previous pregnancy hypertension, levels of cardiovascular risk biomarkers may be modulated by haptoglobin polymorphism.

Authors:  Andreia Matos; Alda Pereira da Silva; Maria Clara Bicho; Conceição Afonso; Maria José Areias; Irene Rebelo; Manuel Bicho
Journal:  Obstet Gynecol Int       Date:  2014-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.